ASCO abstracts are out, and the early standout is a dataset that could reshape the largest oncology franchise in the world. Merck and Kelun-Biotech’s sacituzumab tirumotecan (sac-TMT), a Trop-2 directed antibody-drug conjugate, reduced the risk of disease progression or death by 65% when combined with Keytruda versus Keytruda alone in treatment-naive, PD-L1-positive non-small cell lung cancer. The data come from the Phase 3 OptiTROP-Lung05 trial (HR 0.35, p<0.0001). A preliminary 45% improvement in overall survival was observed but is not yet mature. Fierce Pharma noted this is “the first randomized Phase 3 data showing a Trop-2 ADC can meaningfully improve outcomes” in first-line NSCLC when added to a checkpoint inhibitor. ASCO opens tomorrow. More than 7,000 abstracts will be presented across the conference. Three plenary sessions anchor the meeting on Saturday: Revolution Medicines’ full RASolute 302 data in pancreatic cancer, Akeso’s ivonescimab overall survival data in squamous NSCLC, and J&J’s Erleada PROTEUS data described as a potential “paradigm shift” in high-risk prostate cancer. An oncologist at NewYork-Presbyterian told BioSpace: “There is a palpable sense at this year’s ASCO that we may be entering a fundamentally different era” in GI oncology.
Top Story: sac-TMT Plus Keytruda Cuts Progression Risk by 65% in First-Line Lung Cancer
What Happened: ASCO abstracts released ahead of the meeting revealed that sac-TMT reduced the risk of disease progression or death by 65% when combined with Keytruda versus Keytruda alone in treatment-naive, PD-L1-positive non-small cell lung cancer. The data come from the Phase 3 OptiTROP-Lung05 trial conducted in China.
The Data
The combination achieved a statistically significant PFS improvement (HR 0.35, p<0.0001). A preliminary overall survival analysis showed a 45% improvement in favor of the combination arm, but OS was not mature at the September 29, 2025 data cutoff. Fierce Pharma noted this is “the first randomized Phase 3 data showing a Trop-2 ADC can meaningfully improve outcomes” in first-line NSCLC when added to a checkpoint inhibitor.
Why This Could Extend the Keytruda Franchise Beyond 2028
Keytruda alone is the standard of care for PD-L1-positive first-line NSCLC—the single largest indication in all of oncology by revenue. Adding sac-TMT to Keytruda nearly doubled the efficacy on PFS. The preliminary OS trend points in the same direction.
The strategic insight for Merck is critical: sac-TMT does not replace Keytruda. It makes Keytruda better. A combination regimen that requires both agents—Keytruda plus sac-TMT—would create a new standard of care that extends the Keytruda franchise well beyond its 2028 patent expiration. Even after generic pembrolizumab enters the market, the combination would require branded sac-TMT, giving Merck a protected revenue stream tied to the drug it is about to lose exclusivity on.
The magnitude of the PFS improvement is striking in context. First-line NSCLC is the most competitive indication in oncology. Dozens of combinations have been tested against checkpoint inhibitor monotherapy or chemotherapy-IO combinations over the past decade. Few have demonstrated the kind of clear, statistically robust superiority that sac-TMT showed. An HR of 0.35 means that at any given time point, patients on the combination had roughly one-third the risk of progression compared to patients on Keytruda alone. That level of benefit, if confirmed in OS and in global populations, would make sac-TMT plus Keytruda the most effective first-line regimen in PD-L1-positive lung cancer.
This is the second major Phase 3 win for sac-TMT in a month. The endometrial cancer data on May 20 showed PFS and OS superiority over chemotherapy as a monotherapy. Now the lung cancer data demonstrate that the ADC can improve outcomes in combination with the world’s most prescribed immuno-oncology drug. The Kelun-Biotech partnership is proving to be one of the most productive China licensing deals in the industry, generating registrational-quality data across multiple tumor types in rapid succession.
The China-to-Global Bridge
OptiTROP-Lung05 was conducted in China. Merck’s global trial, TroFuse-007, is evaluating sac-TMT plus Keytruda in PD-L1-high NSCLC patients worldwide. The China data serve as proof of concept; TroFuse-007 will be the basis for U.S. and global regulatory submissions. The consistency between the China endometrial cancer data and the China lung cancer data builds confidence that the TroFuse-007 global results will replicate the findings.
Our Pro brief analyzes why a 65% PFS improvement over Keytruda could extend the franchise beyond its 2028 patent cliff, how the combination thesis changes the Keytruda succession narrative, and what the TroFuse-007 timeline means for a potential U.S. filing. [Details below.]
ASCO Plenary Preview: Three Sessions That Could Move Markets on Saturday
ASCO opens tomorrow with more than 7,000 abstracts spanning oncology’s most active areas. Saturday May 31 features three plenary sessions that each carry the potential to reshape their respective markets.
1. Revolution Medicines RASolute 302: The Pancreatic Cancer Breakthrough
Full Phase 3 data in second-line pancreatic ductal adenocarcinoma. Brian Wolpin, MD (Dana-Farber) presenting. We know the topline: 13.2 months median OS versus 6.7 months (HR 0.40, p<0.0001)—a near-doubling of survival. The plenary will add PFS data (not yet disclosed), subgroup analyses across RAS mutation subtypes and patient characteristics, mature survival curves showing whether the benefit is sustained, and detailed safety data.
Why It Matters: Truist projects a Q3 2026 approval under the CNPV program. If Revolution files shortly after or concurrently with the plenary presentation, the 50-day Foundayo precedent could produce an approval by August or September. The plenary data will determine whether the label is broad or narrow, how quickly oncologists adopt the drug, and whether the commercial trajectory lands at the high or low end of the $2 billion to $4 billion peak sales range.
For pancreatic cancer patients, this is personal. The disease has a five-year survival rate below 15%. Second-line treatment has historically offered months, not years, of additional life. A drug that doubles overall survival in the second line would be the most significant advance against pancreatic cancer in the disease’s history.
2. Akeso Ivonescimab HARMONi-6 OS: Can a Chinese Bispecific Challenge Keytruda?
Overall survival data for ivonescimab, a PD-1/VEGF bispecific antibody developed by China’s Akeso, in squamous NSCLC. Ivonescimab previously showed a 40% PFS improvement over tislelizumab plus chemo in HARMONi-6, and separately beat Keytruda in PFS in HARMONi-02.
Why It Matters: PFS improvements do not always translate to OS benefits—this has been one of the hardest lessons in oncology drug development. If ivonescimab demonstrates a statistically significant overall survival improvement in squamous NSCLC, it would be the first bispecific antibody to show OS superiority in a lung cancer setting and the first Chinese-developed immuno-oncology agent to directly challenge the Keytruda standard of care on the endpoint that matters most. The global implications—for Merck, for the IO competitive landscape, and for the China-to-West licensing model—would be substantial. If ivonescimab’s OS data are positive, expect M&A interest from Western pharma companies seeking to license or acquire the asset for global markets.
3. J&J Erleada PROTEUS: A Paradigm Shift in Prostate Cancer?
Data for Erleada (apalutamide) in high-risk localized or locally advanced prostate cancer, described as a potential “paradigm shift.” Erleada is already approved in metastatic and non-metastatic castration-resistant prostate cancer. A positive PROTEUS result would expand the label into earlier disease stages where patient volumes are significantly larger.
Why It Matters: Moving a prostate cancer therapy from the metastatic setting into high-risk localized disease follows the same trajectory that has expanded ADCs from late-line to first-line treatment. Earlier treatment settings mean larger patient populations and longer treatment durations. PROTEUS opens the plenary on Saturday, setting the tone for the most data-rich day of the conference. If positive, the data would add another indication to the Erleada franchise and reinforce the broader oncology trend of treatments moving earlier in the disease course. Prostate cancer is the most common cancer in men, and high-risk localized disease represents a patient population where intensified systemic therapy could prevent progression to metastatic disease entirely.
ASCO Opens Tomorrow: The Scale of What Is Coming
BioSpace reported that ASCO 2026 will feature more than 7,000 abstracts across every major tumor type and therapeutic modality. The conference will be the most data-rich oncology meeting in years, with key themes spanning ADC combinations (following two first-line approvals in two weeks), bispecific antibodies (ivonescimab challenging checkpoint inhibitor dominance), RAS inhibitors (Revolution’s plenary anchoring the GI oncology narrative), radiopharmaceuticals (Novartis Pluvicto and emerging programs), and cell therapy real-world evidence (CAR-T outcomes across hematologic malignancies).
The commercial implications extend beyond individual presentations. ASCO is where formulary positioning decisions are informed, M&A targets are identified, analyst models are revised, and clinical practice adoption is shaped. With biopharma M&A already at approximately $93 billion through April and multiple therapeutic areas actively consolidating, the data presented this week will catalyze the next wave of deal-making in the months ahead.
We begin daily ASCO coverage tomorrow and will highlight the datasets with the most significant commercial, clinical, and strategic implications for our readers throughout the conference.
Policy: Push to Restrict U.S. Capital Flows to Chinese Biotech
What Happened: Fierce Biotech reported that a growing coalition in Congress wants biotechnology added to the COINS Act, which would restrict outbound U.S. capital flows to designated sectors in countries of concern, including China.
What This Would Mean for the Industry
If enacted, the provision would directly affect U.S. venture capital and private equity investment in Chinese biotech companies. It could also complicate the licensing pipeline that has been one of the defining trends of 2026. Companies with significant China licensing exposure include BMS/Hengrui ($15.2 billion, 13 programs), Lilly/Hengrui (via Kailera), Merck/Kelun-Biotech (sac-TMT and broader ADC collaboration), GSK/SiranBio ($1 billion ALK7), and AbbVie/Haisco.
The legislation would not retroactively unwind existing deals, but could freeze new investments and complicate future milestone payments, royalty structures, and partnership expansions. Combined with China’s Decree No. 834 (which gives Beijing power to scrutinize foreign commercial decisions), the COINS Act would create a pincer dynamic: U.S. restrictions on capital flowing to China from one direction, and Chinese restrictions on how Western companies manage their Chinese partnerships from the other.
The political momentum is building. The BIOSECURE Act debates, the Section 232 tariff framework, China’s Decree No. 834 (which gives Beijing power to scrutinize foreign commercial decisions), and the growing concern about Chinese pharmaceutical manufacturing dependence all feed the same policy narrative. Whether the biotech provision survives the legislative process is uncertain, but its introduction signals that the regulatory environment for China-West pharmaceutical collaboration is tightening from both sides simultaneously.
The irony of the timing is difficult to ignore. The COINS Act push is intensifying at the exact moment the China licensing model is producing its strongest clinical data. sac-TMT’s 65% PFS improvement over Keytruda came from a molecule developed by Kelun-Biotech. BMS’s $15.2 billion Hengrui partnership, Lilly’s Kailera obesity franchise, and GSK’s ALK7 siRNA all trace back to Chinese innovation. The political system is moving to restrict the capital flows that enable these partnerships while the clinical system is generating the data that validate them. Companies operating in this space must navigate both dynamics simultaneously, building contingency plans for restricted capital flows while continuing to execute on partnerships that are delivering value.
Strategic Themes
1. sac-TMT Plus Keytruda Is the Most Important ADC-IO Combination Data in Years
A 65% reduction in progression risk in first-line NSCLC when an ADC is added to the world’s most prescribed immuno-oncology drug is not incremental. It is practice-changing. If confirmed at the full ASCO presentation and replicated in Merck’s global TroFuse-007 trial, the Keytruda plus sac-TMT combination would become the new standard of care in PD-L1-positive lung cancer. That standard would require both agents, creating a protected commercial mechanism for Merck even as Keytruda faces generic competition after 2028.
2. Saturday’s Three Plenaries Will Define the Oncology Narrative for the Rest of 2026
Revolution in pancreatic cancer. Akeso in lung cancer. J&J in prostate cancer. Each plenary carries the potential to establish a new standard of care in its respective indication. The combined impact of three potentially practice-changing datasets presented in a single session has no recent precedent at ASCO. The market’s reaction—stock movements, analyst revisions, M&A discussions—will begin Saturday afternoon and play out for months.
3. The China Licensing Model Is Under Political Pressure Even as It Produces Its Best Clinical Data
sac-TMT’s 65% PFS improvement over Keytruda came from a Kelun-Biotech-developed molecule. Revolution’s daraxonrasib uses technology developed domestically but competes alongside Chinese-developed assets. The COINS Act provision would add capital flow restrictions to the BIOSECURE Act debates and the Decree No. 834 dynamics. The irony is sharp: the political pressure on China-West pharma collaboration is intensifying at the exact moment the clinical returns from that collaboration are proving most valuable.
4. ASCO Opens Tomorrow with More Than 7,000 Abstracts
The volume of data is extraordinary. ADC combinations, bispecific antibodies, RAS inhibitors, radiopharmaceuticals, and cell therapy real-world evidence will all be presented across the conference. We begin daily ASCO coverage tomorrow and will highlight the datasets with the most significant commercial, clinical, and strategic implications for our readers.
Frequently Asked Questions
What did the sac-TMT abstract show?
sac-TMT plus Keytruda reduced the risk of progression or death by 65% (HR 0.35, p<0.0001) versus Keytruda alone in treatment-naive, PD-L1-positive NSCLC. A preliminary 45% OS improvement was observed but is not yet mature. Fierce Pharma called it “the first randomized Phase 3 data showing a Trop-2 ADC can meaningfully improve outcomes” in first-line NSCLC with a checkpoint inhibitor.
Why does the sac-TMT data matter for Keytruda’s future?
The combination creates a new regimen requiring both agents. Even after generic Keytruda enters the market post-2028, the combination would need branded sac-TMT. This extends the franchise’s commercial life by making Keytruda part of a new standard of care rather than a standalone therapy facing generic erosion.
What are the three ASCO plenary sessions?
Revolution Medicines: full Phase 3 RASolute 302 in pancreatic cancer (13.2 months OS vs 6.7 months). Akeso ivonescimab: overall survival in squamous NSCLC (PD-1/VEGF bispecific that previously beat Keytruda on PFS). J&J Erleada PROTEUS: potential paradigm shift in high-risk localized prostate cancer.
What is the OptiTROP-Lung05 trial?
A Phase 3 trial conducted in China evaluating sac-TMT plus Keytruda versus Keytruda alone in first-line PD-L1-positive NSCLC. Merck’s global trial TroFuse-007 is evaluating the same combination and will be the basis for U.S. and global regulatory submissions.
What is the COINS Act?
Legislation that would restrict U.S. outbound capital flows to Chinese companies in designated sectors. A growing Congressional coalition wants biotechnology added. If enacted, it would affect U.S. VC and PE investment in Chinese biotech and could complicate existing licensing partnerships.
How many abstracts are at ASCO?
More than 7,000. Key themes include ADC combinations, bispecific antibodies, RAS inhibitors, radiopharmaceuticals, and cell therapy real-world evidence.
When does ASCO open?
Tomorrow, May 29. Runs through June 2 in Chicago. The plenary sessions on Saturday May 31 are the most anticipated events.
BioMed Nexus Pro — What Institutional Subscribers Are Reading Today
sac-TMT: The Keytruda Succession Plan. We analyze how a 65% PFS improvement positions the sac-TMT/Keytruda combination as the post-patent standard of care in NSCLC, model the revenue implications of a combination regimen that extends the franchise beyond 2028, and assess the TroFuse-007 global trial timeline.
ASCO Plenary Deep Preview. We provide session-by-session analysis of Revolution, Akeso, and J&J—what each dataset needs to show, what the market expects, and how each result changes the competitive landscape in its indication.
China Licensing Under Political Pressure. We map the COINS Act against the BIOSECURE Act, Decree No. 834, and the Section 232 framework to assess the cumulative regulatory risk facing the $50B+ China-West pharma licensing pipeline.
Plus: Full ASCO abstract highlights, 7,000-abstract coverage plan, M&A target identification framework, and the updated catalyst calendar through H2 2026.
About BioMed Nexus
BioMed Nexus delivers institutional-grade intelligence to biotech and pharma executives, investors, and clinicians. Our daily briefings and deep-dive analyses cut through the noise to deliver the strategic insights that drive better decision-making in the life sciences.
Subscribe to receive daily updates and gain access to BioMed Nexus Pro institutional intelligence briefs.
